Previous estimates of the national economic burden of allergic rhinoconjunctivitis (AR/AC) have relied on data analyses in which AR/AC was the primary International Classification of Diseases-ninth revision-Clinical Modification (ICD-9-CM) - coded diagnosis.
These studies ignore the costs when AR/AC was a secondary diagnosis to other disorders such as asthma and sinusitis.
We sought to determine the national direct cost of illness for AR/AC.
An expert panel used the Delphi technique to estimate the proportion of visits coded by other primary ICD-9-CM diagnoses in which AR/AC was a significant secondary comorbid condition.
The costs of this proportion were deemed to be attributable'to AR/AC and were added to the costs when allergic rhinitis and allergic conjunctivitis were the primary diagnoses.
The cost when AR/AC was the primary diagnosis was $1.9 billion (in 1996 dollars).
The cost when AR/AC was a secondary diagnosis was estimated at $4.0 billion, giving an estimate of $5.9 billion for the overall direct medical expenditures attributable to AR/AC.
Outpatient services (63%, $3.7 billion), medications (25%, $1.5 billion), and inpatient services (12%, $0.7 billion) accounted for the expenditures.
Children 12 years and younger accounted for $2.3 billion (38.0%). Conclusion : Upper airway allergy is an expensive disease process because of its readily apparent manifestations as AR/AC and its contribution to other airway disorders.
Mots-clés Pascal : Rhinite, Allergie, Conjonctivite, Coût, Economie santé, Age, ORL pathologie, Nez pathologie, Immunopathologie, Oeil pathologie, Conjonctive pathologie
Mots-clés Pascal anglais : Rhinitis, Allergy, Conjunctivitis, Costs, Health economy, Age, ENT disease, Nose disease, Immunopathology, Eye disease, Conjunctiva disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0187233
Code Inist : 002B30A01C. Création : 16/11/1999.